Transgene S.A.

Transgene S.A. is a French biotechnology company established in 1979, dedicated to the design and development of targeted immunotherapies for cancer treatment. Headquartered in Illkirch-Graffenstaden, near Strasbourg, France, the company's core mission is to harness and stimulate the immune system to recognize and eliminate cancer cells, primarily through the use of viral vector technology.

Transgene's product pipeline focuses on immunotherapies derived from two key technological platforms: myvac®, which develops individualized therapeutic vaccines, and Invir.IO®, which focuses on oncolytic viruses. The company's clinical-stage assets include TG4050, an individualized neoantigen therapeutic vaccine currently in Phase 1/2 trials for head and neck cancer, and TG4001, a therapeutic vaccine for HPV-16 positive cancers. Other programs, such as the oncolytic viruses BT-001 and TG6050, are also in clinical development.

Under the leadership of Chairman and CEO Alessandro Riva, who assumed the role in May 2023, Transgene recently completed a fundraising round of approximately €105 million in November 2025. This capital is intended to accelerate the development of its myvac® platform and extend the company's financial visibility until early 2028. In April 2026, Transgene announced the completion of patient randomization for the Phase 2 part of its TG4050 clinical trial in head and neck cancer and signed a licensing agreement with NEC Bio for further development of TG4050 in this indication.

Latest updates

Transgene Secures NEC Bio Partnership, Extends Financial Runway

Event summary

  • Transgene completed enrollment in Phase 2 of its TG4050 head and neck cancer trial, with topline data expected by the end of Q1 2028.
  • The company published Phase 1 data for TG4050 on medRxiv and presented it at the World Vaccine Congress.
  • Transgene signed a license agreement with NEC Bio, securing access to NEC’s AI-based neoantigen prediction platform and €2.5 million in payments.
  • Transgene’s Q1 2026 revenue decreased to €1.4 million, primarily due to reduced research tax credits.
  • The company maintains €103.8 million in cash, providing financial visibility until early 2028.

The big picture

Transgene's partnership with NEC Bio represents a strategic move to leverage AI in personalized cancer immunotherapy, a rapidly growing area within the biotech sector. The deal provides both financial support and technological expertise, but also introduces dependency on a third party. The company's focus on individualized neoantigen vaccines addresses a significant unmet need in treating HPV-negative head and neck cancers, a market segment with limited treatment options.

What we're watching

Clinical Outcomes
The 2-year disease-free survival data expected in Q2/Q3 2026 will be critical in validating TG4050’s efficacy and influencing future development decisions.
Partner Integration
How effectively Transgene integrates NEC Bio’s AI platform into its neoantigen selection process will impact the speed and efficiency of future vaccine development.
Financial Sustainability
The pace of milestone payments from NEC Bio and the ability to secure additional funding will determine if Transgene can maintain its financial runway beyond early 2028.
CID: 1960